Novo Nordisk shares tumbled roughly 10% on Friday after the Danish drugmaker announced that its experimental heart medicine ziltivekimab failed to meet the primary goal of a key late-stage clinical trial.
The company said the anti-inflammatory drug did not produce a statistically meaningful reduction in major adverse cardiovascular events, a setback for one of its most closely watched pipeline candidates beyond its blockbuster diabetes and obesity franchises.
Ziltivekimab had been positioned as a potential growth driver as Novo Nordisk seeks to diversify beyond the semaglutide products that power its Wegovy and Ozempic brands. The treatment targets inflammation as a driver of cardiovascular disease, an approach the company had hoped would open a substantial new market.
“The trial did not demonstrate a statistically significant reduction in major adverse cardiovascular events,” Novo Nordisk stated, adding that it would continue to review the full data set.
The disappointing readout adds pressure on a company already navigating intensifying competition in the weight-loss market and a period of internal transition. Earlier this year, the drugmaker’s leadership shake-up underscored the mounting strategic stakes facing the firm as rivals close the gap.
Investors have grown increasingly sensitive to Novo Nordisk’s pipeline results, with the company’s valuation heavily tied to expectations of sustained innovation. The share decline erased a significant portion of market value in a single session.
The setback contrasts with recent positive readouts elsewhere in the company’s portfolio, including cardiovascular benefits demonstrated by its oral treatment. Analysts have suggested the diversification of Novo Nordisk’s research portfolio remains critical as patent and competitive pressures build in the coming years.
The company said it would provide further details on the trial outcome and its implications for the ziltivekimab development programme at a later date, while reaffirming its broader research commitments.